- Citations, last 5 years
- 18
- Works, last 5 years
- 18
- h-index
- 27
- Scientists listed
- 4
- Grants since 2016
- 8
Grants received
2021 · research · R43
Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19
Mark Newman · GeoVax (United States) · funded by National Institutes of Health
2018–2023 · grant · PRMRP
Advanced Preclinical Development and Production of Master Seed Virus of GEO-LM01, a Novel MVA-VLP Vaccine Against Lassa Fever
Mark Newman · GeoVax (United States) · funded by Congressionally Directed Medical Research Programs
2018–2020 · research · R44
Construction and efficacy testing of novel recombinant vaccine designs for eliciting both broadly neutralizing antibodies and T cells against Lassa virus
Farshad Guirakhoo · GeoVax (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus
Farshad Guirakhoo · GeoVax (United States) · funded by National Institutes of Health
2017–2019 · research · R43
Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus
Farshad Guirakhoo · GeoVax (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Enhancing protective antibody responses for a DNA/MVA HIV vaccine
Harriet L Robinson · GeoVax (United States) · funded by National Institutes of Health
2016–2017 · contract · N01
IGF::OT::IGF STAGE VACCINE DEVELOPMENT
Harriet Robinson · GeoVax (United States) · funded by National Institutes of Health
2016–2018 · research · R44
Enhancing protective antibody responses for a DNA/MVA HIV vaccine
Harriet L Robinson · GeoVax (United States) · funded by National Institutes of Health